Targeting Angiogenesis with a Novel Therapy for Wet Age Related Macular Degeneration


Healthcare - Pharmaceuticals & Therapeutics
Chemicals - Bio-based
United Kingdom


Age-related macular degeneration (AMD) is a progressive retinal disease that is the leading cause of central vision loss in developed countries, affecting 1 in 10 people older than 50 years. AMD is characterised by abnormal formation of blood vessels (angiogenesis) at the back of the eye. These leak fluid and blood into the ocular tissue eventually causing retinal detachment and vision loss. The pro-angiogenic vascular endothelial growth factor (VEGF) is a major driver of new blood vessel formation in this disease. Current therapies block VEGF from stimulating pro-angiogenic responses, whereas QM107 directly targets an endogenous cell surface receptor which stimulates an anti-angiogenic response by reducing vascular permeability and endothelial cell migration. Current therapies which target VEGF: 1) Associated with high level of patient non-response and side effects (cardiac infarct, thromboembolic events, micro-angiopathy, etc.). 2) Expensive (£ 1000/ injection of Lucentis) and very invasive: They involve injecting antibodies directly into the eyes of patients on a monthly basis. 3) Evidence that over time (~2 years) their efficacy is lost in 10- 20% of cases and patient’s sight worsens.


  • QM107 is a small, stable peptide with potent anti-angiogenic effects which have been demonstrated in various cancer and ocular disease models
  • QM107 does not affect cell proliferation, has a negligible toxicity profile in vitro and based on proteomic analysis has very few off-target effects as well as no effect in cells of epithelial origin
  • QM107 prevents vessels leaking at the back of the eye by reducing vascular permeability
  • High level of stability: 75% availability at 24hrs at 37 ○C in either rat or human serum. Not cleaved by proteases
  • QM107 inhibits choroidal neo-vascularisation in vitro as effectively as Eylea
  • QM107 provides an optimal 50% reduction in angiogenic sprouts from choroid explants
  • QM107 is not toxic to Human ECs even at very high doses


This method has the potential of administration as an eye drop formulation, representing a substantial improvement for patient experience, well- being and comfort.


  1. New potent anti-angiogenic peptide that could be used either in combination or as an alternative treatment for patients who do not respond to current therapies e.g. Lucentis or Eylea (25%-45% of patients not responsive)
  2. Cost effective and scalable chemical synthesis (demonstrated) via eGMP standard production, which presents less challenges than producing antibody based therapies.
  3. Based on in vivo testing the effective dose range is well within what would be feasible to administer to the human eye and lower than Lucentis (~2μg, while Lucentis is used at 0.5 mg/injection) and Eylea (2mg/ injection)
  4. Has potential of administration as an eye drop formulation, representing a substantial improvement for patient experience, well- being and comfort.
Therapeutic Inhibitor for Epstein-Barr Virus (EBV)-associated Cancers
Cancer Catcher - Early Detection of Circulating Tumour Cells
Potent Anti-bacterial Plant Oil for Skin Health and Ailment
Melanin Derived From Black Soldier Flies
Non-Invasive, Non-Toxic Encapsulation Technology to Prolong Effects of Leave-on Products
Novel Anti-microbial Agent for Preventing Dental Caries
Non-invasive Alzheimer’s Disease Diagnostic Kit
Growth Factor-free Proliferation & Differentiation of Stem Cell
A modified Chinese Medicine formulation for treating Alzheimer's disease
Plant-Harvested Biopolymer for Postsurgical Adhesion Barrier Gel and Film Application